Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

Ricardo Hitt; Lara Iglesias Docampo; Antonio López Pousa; Alfonso Berrocal Jaime; Juan J. Grau de Castro; Carlos García Girón; Javier Martínez Trufero; Marta Guix; Julio José Lambea Sorrosal; Edel del Barco Morillo; Xavier León Vintró; A.J. Cunquero Tomás; Neus Basté Rotllan; Alberto Ocaña; Juan Jesús Cruz Hernández

Ayuda

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

R. Hitt ^[1] ; L. Iglesias ^[9] ; A. López-Pousa ^[2] ; A. Berrocal-Jaime ^[3] ; J.J. Grau ^[4] ; C. García-Girón ^[5] ; J. Martínez-Trufero ^[6] ; M. Guix ^[7] ; J. Lambea-Sorrosal ^[10] ; E. del Barco-Morillo ^[8] ; X. León-Vintró ^[2] ; A.J. Cunquero-Tomas ^[3] ; N. Baste ^[4] ; A. Ocaña ^[8] ; J.J. Cruz-Hernández ^[8]
1. [1] Hospital Severo Ochoa
  
  Hospital Severo Ochoa
  
  Madrid, España
2. [2] Hospital de la Santa Creu i Sant Pau
  
  Hospital de la Santa Creu i Sant Pau
  
  Barcelona, España
3. [3] Hospital General Universitario de Valencia
  
  Hospital General Universitario de Valencia
  
  Valencia, España
4. [4] Hospital Clinic Barcelona
  
  Hospital Clinic Barcelona
  
  Barcelona, España
5. [5] Complejo Asistencial Universitario de Burgos
  
  Complejo Asistencial Universitario de Burgos
  
  Burgos, España
6. [6] Hospital Miguel Servet
  
  Hospital Miguel Servet
  
  Zaragoza, España
7. [7] Hospital del Mar
  
  Hospital del Mar
  
  Barcelona, España
8. [8] Hospital Universitario de Salamanca
  
  Hospital Universitario de Salamanca
  
  Salamanca, España
9. [9] Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid
10. [10] Medical Oncology Department, Hospital Clínico Lozano Blesa, Zaragoza
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 4, 2021, págs. 764-772
Idioma: inglés
Texto completo no disponible (Saber más ...)

Dialnet Métricas: 2 Citas

Resumen
- Background Our previous phase-3 study (TTCC 2503) failed to show overall survival advantage of 2 induction chemotherapy (IC) regimens followed by standard concurrent chemoradiotherapy (CRT) over CRT alone in patients with unresectable locally advanced head and neck squamous-cell carcinoma (LAHNSCC). This study described the long-term survival of those patients.
  
  Materials and methods Long-term follow-up study of patients with untreated LAHNSCC assigned to IC (three cycles), with either docetaxel, cisplatin and 5-fluorouracil (TPF arm) or cisplatin and 5-fluorouracil (PF arm), followed by CRT, or CRT alone, included in the previous TTCC 2503 trial.
  
  Results In the intention-to-treat population (n = 439), the median OS times were 25.4 (95% CI, 16.8–34.4), 26.2 (95% CI, 18.2–36.6) and 25.4 months (95% CI, 17.4–36.0) in the TPF-CRT, PF-CRT and CRT arms, respectively (log-rank p = 0.51). In the per-protocol population (n = 355), patients with larynx–hypopharynx primary tumors treated with IC (TPF or PF) followed by CRT had a longer median PFS than those who received CRT alone. Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes.
  
  Conclusion After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in unresectable LAHNSCC regarding the primary end point. However, fit patients with ECOG 0 and primary larynx–hypopharyngeal tumors may benefit from the use of IC if administered by an experienced team.